PubMed HealthSearch

PubMed · 7571845

Congress objectives.

Abstract

In 1993, the Viral Hepatitis Prevention Board (VHPB) recognized that selective vaccination of individuals at high risk from hepatitis B had failed to control the spread of hepatitis B. The Action towards Control of Hepatitis B as a Community Health Risk was therefore established to provide information and make recommendations on actions to take to combat hepatitis B in the community. The VHPB supports the World Health Organization (WHO) recommendation that universal hepatitis B vaccination for all infants and/or adolescents should be integrated into the national immunization programme in all countries by 1997. The VHPB met regularly throughout 1993 to consider the issues involved in implementing universal strategies and to develop practical solutions that can help all countries meet the WHO goal. During this congress the feasibility of implementing universal infant and/or adolescent vaccination strategies were explored by reviewing the seroprevalence data in Europe, development of cost-benefit models and progress in countries that have already implemented universal vaccination. With the delegates' input, resolutions were reached that will guide future action towards meeting the WHO goal and combating hepatitis B in the community.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Roure. 1995. Congress objectives.. https://doi.org/10.1016/0264-410x(95)80036-d

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A practical guide to the use of interferons in the management of hepatitis virus infections.

The recommended interferon dosage for patients with chronic hepatitis and typical hepatitis B virus (HBV) infection is 10 MU 3 times weekly for 4 to 6 months; with such a regimen sustained alanine aminotransferase (ALT) normalisation, liver histology improvement, clearance of HBV DNA and seroconversion from hepatitis B e antigen (HBeAg) to anti-HBe are obtained in about 40% of treated patients. Patients with elevated disease activity (high ALT values, active chronic hepatitis, low HBV DNA levels) tend to respond better to therapy; Oriental patients and immunocompromised patients are not ideal candidates for interferon. Patients with chronic hepatitis B and the HBeAg-negative variant should be given intermediate dosages (6 to 9 MU thrice weekly) of interferon for prolonged periods (12 months); however, even with this approach, the relapse rate is high (> 60%) during the follow-up. In chronic hepatitis D virus (HDV) infection, therapy with 9 to 10 MU of interferon 3 times weekly for 12 months induces a transient remission in disease (ALT normalisation, HDV RNA clearance) in more than 50% of treated patients, but a sustained response is found in less than 20% of patients. In such disease, baseline predictive factors of long term response are still unknown. In chronic hepatitis C, treatment with 3 to 5 MU of interferon given 3 times weekly for 6 to 12 months induces a sustained remission in no more than 30% of treated patients. Probable predictive factors of long term response are: low viraemia, genotype other than 1, absence of cirrhosis, low intrahepatic iron content, low nucleotide diversity of the envelope 2 gene of the hepatitis C virus. Prolonged (> 12 months) therapeutic courses seem to enhance the sustained response rate; in nonresponders/relapsers, combined therapy (interferon plus indomethacin, interferon plus ketoprofen, interferon plus ribavirin) is promising but randomised controlled trials are needed in order to establish the real efficacy and safety of such therapeutic regimens.

Hepatitis B

The heritage of hepatitis B vaccine.

Pioneering development of the plasma-derived and yeast-derived recombinant hepatitis B vaccines represents a major contribution to preventive health care of this century. Current and expanding worldwide application of hepatitis B vaccine promises to eliminate and eventually eradicate hepatitis B infection from the human population and, with it, many cases of cirrhosis and cancer of the liver.

Hepatitis B